Dr. Quay featured on LateNight Health Radio

Dr. Stephen Quay, CEO of Atossa Therapeutics, discusses the origins of COVID-19, presenting evidence from his recently released paper suggesting it likely originated in a laboratory. Quay explains Bayesian analysis used in his research, indicating a high probability of lab origin. He delves into the concept of gain-of-function research and its potential role in inadvertently creating the virus. Quay also touches on the importance of therapeutics alongside vaccines, highlighting his company’s developments in nasal sprays and treatments to prevent severe cases. Additionally, he advocates for vaccinations and discusses his book “Stay Safe,” offering insights into health strategies, including nutrition and supplements. The conversation concludes with an invitation for future discussions on late-night health.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies